Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim + all-trans retinoic acid + azacitidine for higher-risk myelodysplastic syndromes
ChiCTR2600131180Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mecapegfilgrastim, tretinoin and azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Overall response rate and Overall survival and overall survival rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mecapegfilgrastimtretinoinazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600131180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131180.